For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

A proposed buyout of Bavarian Nordic by a private equity consortium didn’t win over enough shareholder support, laying to ...

Incyte has expanded its support for projects tackling unmet needs to cover hidradenitis suppurativa (HS) patients, tightening ...

Eli Lilly and Novo Nordisk have become the latest pharma giants to strike price-reduction deals with the White House, agreeing to sell their weight loss drugs at cut-rate prices to patients in the U.S ...